E2F1 Induces Tumor Cell Survival via Nuclear Factor-κB-Dependent Induction of EGR1 Transcription in Prostate Cancer Cells

被引:54
作者
Zheng, Chaogu [2 ]
Ren, Zijia [2 ]
Wang, Hetian [2 ]
Zhang, Weici [2 ]
Kalvakolanu, Dhananjaya V. [3 ]
Tian, Zhigang [2 ]
Xiao, Weihua [1 ,2 ]
机构
[1] Univ Sci & Technol China, Inst Immunol, Sch Life Sci, Hefei 230027, Anhui, Peoples R China
[2] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China
[3] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA
基金
中国国家自然科学基金;
关键词
SIGNAL-TRANSDUCTION; ANDROGEN RECEPTOR; GROWTH-FACTORS; TARGET GENES; APOPTOSIS; ACTIVATION; EXPRESSION; PHOSPHORYLATION; TUMORIGENESIS; ROLES;
D O I
10.1158/0008-5472.CAN-08-4113
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Transcription factor E2F1 has been implicated in both apoptosis-promoting and apoptosis-suppressing effects. However, factors that mediate its antiapoptotic effects are still not identified. Using prostate tumor-derived cell lines, we showed here that E2F1 activated the expression of transcription factor EGR1 for promoting cell survival. E2F1 up-regulated the production of EGR1-induced growth factors, epidermal growth factor, platelet-derived growth factor, and insulin-like growth factor 11, which in turn activated the phosphoinositide-3-kinase/Akt pathway to resist drug-induced apoptosis. Moreover, E2F1 directly induced the transcription of the Egr1 gene using the kappa B site located in its proximal promoter. E2F1 physically interacted with the RelA subunit of nuclear factor-kappa B and modulated its transactivity to fully activate EGR1 transcription. Together, these studies uncovered a novel mechanism for E2F1-induced suppression of apoptosis in prostate cancer. [Cancer Res 2009;69(6):2324-31]
引用
收藏
页码:2324 / 2331
页数:8
相关论文
共 47 条
[1]   Mechanisms of prostate tumorigenesis: Roles for transcription factors Nkx3.1 and Egr1 [J].
Abdulkadir, SA .
TUMOR PROGRESSION AND THERAPEUTIC RESISTANCE, 2005, 1059 :33-40
[2]   Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma [J].
Abdulkadir, SA ;
Carbone, JM ;
Naughton, CK ;
Humphrey, PA ;
Catalona, WJ ;
Milbrandt, J .
HUMAN PATHOLOGY, 2001, 32 (09) :935-939
[3]   Impaired prostate tumorigenesis in Egr1-deficient mice [J].
Abdulkadir, SA ;
Qu, ZC ;
Garabedian, E ;
Song, SK ;
Peters, TJ ;
Svaren, J ;
Carbone, JM ;
Naughton, CK ;
Catalona, WJ ;
Ackerman, JJH ;
Gordon, JI ;
Humphrey, PA ;
Milbrandt, J .
NATURE MEDICINE, 2001, 7 (01) :101-107
[4]  
Adamson E, 2003, CANCER BIOL THER, V2, P617
[5]   Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence [J].
Agus, DB ;
Cordon-Cardo, C ;
Fox, W ;
Drobnjak, M ;
Koff, A ;
Golde, DW ;
Scher, HI .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (21) :1869-1876
[6]   Analysis of functional elements in the human Egr-1 gene promoter [J].
Aicher, WK ;
Sakamoto, KM ;
Hack, A ;
Eibel, H .
RHEUMATOLOGY INTERNATIONAL, 1999, 18 (5-6) :207-214
[7]   Signal transduction via the NF-κB pathway:: a targeted treatment modality for infection, inflammation and repair [J].
Ali, S ;
Mann, DA .
CELL BIOCHEMISTRY AND FUNCTION, 2004, 22 (02) :67-79
[8]   The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFβ1, PTEN, p53, and fibronectin [J].
Baron, V ;
Adamson, ED ;
Calogero, A ;
Ragona, G ;
Mercola, D .
CANCER GENE THERAPY, 2006, 13 (02) :115-124
[9]   Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo [J].
Baron, V ;
De Gregorio, G ;
Krones-Herzig, A ;
Virolle, T ;
Calogero, A ;
Urcis, R ;
Mercola, D .
ONCOGENE, 2003, 22 (27) :4194-4204
[10]   Unbiased location analysis of E2F1-binding sites suggests a widespread role for E2F1 in the human genome [J].
Bieda, M ;
Xu, XQ ;
Singer, MA ;
Green, R ;
Farnham, PJ .
GENOME RESEARCH, 2006, 16 (05) :595-605